ERBB2 and breast cancer: In a phase I study evaluating the combination of T-DM1 and pembrolizumab in 20 patients with HER2-positive metastatic BC, several immune biomarkers were tested by immunohistochemistry, whole-exome sequencing (WES), and bulk RNA sequencing (RNA-seq).